Advanced search
1 file | 332.16 KB

Myelofibrosis patients in Belgium : disease characteristics

(2015) ACTA CLINICA BELGICA. 70(2). p.105-111
Author
Organization
Abstract
Objective: To date, only a small number of epidemiological studies on myelofibrosis have been performed. The current study aimed to characterize the myelofibrosis patient population in Belgium according to pre-defined disease parameters (diagnosis, risk categories, hemoglobin,10 g/dl, spleen size, constitutional symptoms, platelet count, myeloblast count), with a view to obtaining a deeper understanding of the proportion of patients that may benefit from the novel myelofibrosis therapeutic strategies. Methods: A survey was used to collect data on prevalence and disease parameters on all myelofibrosis patients seen at each of 18 participating hematologic centers in 2011. Aggregated data from all centers were used for analysis. Analyses were descriptive and quantitative. Results: A total of 250 patients with myelofibrosis were captured; of these, 136 (54%) were male and 153 (61%) were over 65 years old. One hundred sixty-five (66%) of myelofibrosis patients had primary myelofibrosis and 85 (34%) had secondary myelofibrosis. One hundred ninety-three myelofibrosis patients (77%) had a palpable spleen. About a third of patients (34%) suffered from constitutional symptoms. Two hundred twenty-two (89%) myelofibrosis patients had platelet count >= 50 000/mu l and 201 (80%) had platelet count >= 100 000/mu l. Of 250 patients, 85 (34%) had a myeloblast count similar to 1%. Six (2%) patients had undergone a splenectomy. Thirteen (5.2%) patients had undergone radiotherapy for splenomegaly. Conclusions: The results of this survey provide insight into the characteristics of the Belgian myelofibrosis population. They also suggest that a large proportion of these patients could stand to benefit from the therapies currently under development.
Keywords
Management, INTERNATIONAL WORKING GROUP, Characteristics, Prevalence, Myelofibrosis, STEM-CELL TRANSPLANTATION, TYROSINE KINASE JAK2, MYELOPROLIFERATIVE DISORDERS, MYELOID MALIGNANCIES, POLYCYTHEMIA-VERA, AVAILABLE THERAPY, RUXOLITINIB, SURVIVAL, EFFICACY

Downloads

  • 2295333714Y 2E0000000097.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 332.16 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Devos, T, P Zachée, D Bron, Lucien Noens, J Van Droogenbroeck, P Mineur, Y Beguin, et al. 2015. “Myelofibrosis Patients in Belgium : Disease Characteristics.” Acta Clinica Belgica 70 (2): 105–111.
APA
Devos, T., Zachée, P., Bron, D., Noens, L., Van Droogenbroeck, J., Mineur, P., Beguin, Y., et al. (2015). Myelofibrosis patients in Belgium : disease characteristics. ACTA CLINICA BELGICA, 70(2), 105–111.
Vancouver
1.
Devos T, Zachée P, Bron D, Noens L, Van Droogenbroeck J, Mineur P, et al. Myelofibrosis patients in Belgium : disease characteristics. ACTA CLINICA BELGICA. 2015;70(2):105–11.
MLA
Devos, T, P Zachée, D Bron, et al. “Myelofibrosis Patients in Belgium : Disease Characteristics.” ACTA CLINICA BELGICA 70.2 (2015): 105–111. Print.
@article{5970812,
  abstract     = {Objective: To date, only a small number of epidemiological studies on myelofibrosis have been performed. The current study aimed to characterize the myelofibrosis patient population in Belgium according to pre-defined disease parameters (diagnosis, risk categories, hemoglobin,10 g/dl, spleen size, constitutional symptoms, platelet count, myeloblast count), with a view to obtaining a deeper understanding of the proportion of patients that may benefit from the novel myelofibrosis therapeutic strategies. 
Methods: A survey was used to collect data on prevalence and disease parameters on all myelofibrosis patients seen at each of 18 participating hematologic centers in 2011. Aggregated data from all centers were used for analysis. Analyses were descriptive and quantitative. 
Results: A total of 250 patients with myelofibrosis were captured; of these, 136 (54\%) were male and 153 (61\%) were over 65 years old. One hundred sixty-five (66\%) of myelofibrosis patients had primary myelofibrosis and 85 (34\%) had secondary myelofibrosis. One hundred ninety-three myelofibrosis patients (77\%) had a palpable spleen. About a third of patients (34\%) suffered from constitutional symptoms. Two hundred twenty-two (89\%) myelofibrosis patients had platelet count {\textrangle}= 50 000/mu l and 201 (80\%) had platelet count {\textrangle}= 100 000/mu l. Of 250 patients, 85 (34\%) had a myeloblast count similar to 1\%. Six (2\%) patients had undergone a splenectomy. Thirteen (5.2\%) patients had undergone radiotherapy for splenomegaly. 
Conclusions: The results of this survey provide insight into the characteristics of the Belgian myelofibrosis population. They also suggest that a large proportion of these patients could stand to benefit from the therapies currently under development.},
  author       = {Devos, T and Zach{\'e}e, P and Bron, D and Noens, Lucien and Van Droogenbroeck, J and Mineur, P and Beguin, Y and Berneman, Z and Benghiat, FS and Kentos, A and Chatelain, C and Demuynck, H and Lemmens, J and Van Eygen, K and Theunissen, K and Trullemans, F and Pierre, P and Pluymers, W and Knoops, L},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  language     = {eng},
  number       = {2},
  pages        = {105--111},
  title        = {Myelofibrosis patients in Belgium : disease characteristics},
  url          = {http://dx.doi.org/10.1179/2295333714Y.0000000097},
  volume       = {70},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: